Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04411225 · ClinicalTrials.gov registry record · Phase 3
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
A Phase 3 study of Early Psychosis, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT04411225 is a Phase 3 study of Early Psychosis that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 120 participants, below the 16,773-participant average among 3 other Early Psychosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04411225, a Phase 3 study of Early Psychosis, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.
Conditions Studied
Interventions
- DRUG Cannabidiol oral solution
Study Locations (2)
California
- UC San Diego - La Jolla
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04411225
The ClinicalTrials.gov registry entry for NCT04411225 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,773-participant average among 3 other Early Psychosis trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Psychosis appearing as the primary indexed condition, and to 1 intervention - of which Cannabidiol oral solution is the first listed.
NCT04411225 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04411225 about?
NCT04411225 is a clinical study titled "Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis". This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will e...
What is the current status of trial NCT04411225?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2022-06-01. Estimated completion is 2026-12.
What conditions does trial NCT04411225 study?
This clinical trial studies the following conditions: Early Psychosis.
What interventions are being tested in trial NCT04411225?
The interventions under investigation include: Cannabidiol oral solution (DRUG).
Who is sponsoring clinical trial NCT04411225?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04411225 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.